The development of rapidly acting insulin analogs, novel insulin pump technologies, and continuous glucose sensors (CGM) equipped with highly sophisticated algorithms, operating in the interstitial fluid (semi‐closed‐loop artificial pancreas), have significantly improved the quality of clinical care of diabetes. The gene discussed is INS; the disease is diabetes mellitus.